Concord Biotech Limited IPO
Concord Biotech Limited IPO is listed on BSE and NSE, priced at ₹705–₹741 per share. The stock debuted at ₹900.05, delivering a listing gain of 21.5%. The IPO had a lot size of ₹20 shares and a minimum investment of ₹14,820.
Concord Biotech Limited IPO
- IPO Dates
- Aug 4, 2023 – Aug 8, 2023
- Price band
- ₹705-741 per equity share
- Minimum Investment
- ₹14,820
- Issue size
- Offer for Sale : 20,925,652 shares(aggregating up to ₹1,551.00 Cr)
- Lot size
- 20
- Allotment Date
- Aug 11, 2023
- Listing
- Aug 18, 2023
- Listing At
- BSE, NSE
IPO timeline
-
Aug 4, 2023
Open Date
Completed
-
Aug 8, 2023
Close Date
Completed
-
Aug 11, 2023
Allotment Date
Completed
-
Aug 18, 2023
Listing Date
Completed
Price Summary
- Last closing
- 1,131.00 (52.63%)
- 52 week high
- 2,150.40
- 52 week low
- 987.00
- Last update
Concord Biotech Limited IPO Essentials
Concord Biotech Limited IPO Details
Concord Biotech Limited IPO is priced at ₹705-741 per share with a total issue size of Offer for Sale : 20,925,652 shares(aggregating up to ₹1,551.00 Cr). The IPO has a lot size of 20 shares and is listed on BSE and NSE.
- Issue price
- ₹705-741 per equity share
- Lot size
- 20 shares
- Face value
- ₹1 Per Equity Share
- Issue size
- Offer for Sale : 20,925,652 shares(aggregating up to ₹1,551.00 Cr)
- Listing at
- BSE, NSE
- List price
- 900.05(NSE)
- Listing date
- Registrar
- Link Intime India Private Limited
- Lead manager
-
Kotak Mahindra Capital Company Limited, Citigroup Global Markets India Private Limited, Jefferies India Private Limited
Concord Biotech Limited IPO Analytics
Concord Biotech Limited IPO category-wise subscription trends show day-wise participation across QIB, NII, and retail investors.
Concord Biotech Limited IPO Subscription Status
Concord Biotech Limited IPO subscription status shows demand across retail, NII, and QIB categories, helping investors understand overall participation trends.
The IPO subscription status indicates investor demand across categories.
| As on | QIB |
NII
bHNI
sHNI
|
Retail | Employee | Total |
|---|---|---|---|---|---|
| Shares Offered / Reserved | 4,183,130 |
3,137,348
2,091,565
1,045,783
|
7,320,479 | 10,000 | 14,650,957 |
|
Day 1
04-08-23 05:00 PM
|
0.01 x |
1.01x
0.96x
1.11x
|
0.72 x | 5.73 x | 0.58 x |
|
Day 2
07-08-23 05:00 PM
|
1.61 x |
5.22x
5.12x
5.42x
|
2.26 x | 15.68 x | 2.72 x |
|
Day 3
08-08-23 05:00 PM
|
67.67 x |
16.99x
19.30x
12.36x
|
3.77 x | 24.39 x | 24.86 x |
|
Total No. of Applications
|
category wise applications | ||
|---|---|---|---|
| 12,63,516 (Approx) | 3.45 | ||
Concord Biotech Limited Valuations
Earnings
- EPS (Post IPO)
- ₹22.95/-
- P/E Ratio
- 32.3
Returns
- RoNW
- 20.06%
Concord Biotech Limited Financials( In Crs.)
| 31-Mar-23 | 31-Mar-22 | 31-Mar-21 | |
|---|---|---|---|
| Assets | 1,513.98 | 1,312.80 | 1,182.55 |
| Revenue | 888.48 | 736.35 | 630.75 |
| Profit After Tax | 240.08 | 174.93 | 234.89 |
Concord Biotech Limited Company & Offer Insights
About Concord Biotech Limited
Concord Biotech Limited is an India-based R&D-driven biopharma company. The company is ranked among the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in 2022.
Concord Biotech has a Global presence. They are supplying their products to over 70 countries including the USA, India, Europe, and Japan.
The company manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations. It started with a single product and has grown to become a wide-spectrum solution provider.
Concord manufactures fermentation and semi-synthetic-based products in therapeutic segments such as Immunosuppressants, Anti-bacterial, Oncology, Antifungals & others. This wide range of products has attracted customers across the globe. Concord also has a robust pipeline of products under development.
Concord Biotech Limited Promoter(s)
Mr. Sudhir Vaid, Mr. Ankur Vaid are the company's promoters of Concord Biotech Limited.
Concord Biotech Limited IPO Issue Objectives
- •
- Achieve the benefits of listing the Equity Shares on the Stock Exchanges.
- •
- Carry out the Offer for Sale of up to 20,925,652 Equity Shares by the Selling Shareholder.
Concord Biotech Limited IPO - Anchor Investors
Concord Biotech raises Rs 465 crore from anchor investors ahead of IPO.
The government of Singapore, Abu Dhabi Investment Authority, Government Pension Fund Global, Polar Capital Funds, HSBC Mutual Fund, WF Asian Reconnaissance Fund, Amundi Funds, The Prudential Assurance Company and Pinebridge Global Funds are the marquee investors that participated in the anchor book of the professionally-managed biotech firm.
Apart from that, Nippon Life, UTI Mutual Fund, DSP Mutual Fund, Franklin Mutual Fund, SBI Life Insurance, Motilal Oswal Mutual Fund, Edelweiss Trusteeship, Invesco India, Bandhan Mutual Fund, Aditya Birla Sun Life, Max Life Insurance and Tata AIA Life Insurance also invested in the company via anchor book.
Concord Biotech Limited IPO - Peers Comparison
| P/B Ratio | P/E Ratio | RoNW | Revenue(in Cr.) | |
|---|---|---|---|---|
| Concord Biotech | 6.01 | 32.3 | 20.06% | 888 |
| Divi's Lab | 7.77 | 54.4 | 14.9% | 7,768 |
| Suven Pharma | 7.25 | 30.6 | 25.2% | 1,340 |
| Laurus Labs | 4.49 | 33.6 | 20.4% | 5,386 |
Contact Information
Frequently Asked Questions
Click any question to reveal the answer
Concord Biotech Limited IPO is a book-built IPO worth ₹Offer for Sale : 20,925,652 shares(aggregating up to ₹1,551.00 Cr). The price band is ₹705–₹741 per share. The IPO opens on Aug 4, 2023 and closes on Aug 8, 2023. It will be listed on BSE and NSE. Link Intime India Private Limited is the registrar.
The price band of Concord Biotech Limited IPO is ₹705 to ₹741 per share.
The lot size of Concord Biotech Limited IPO is 20 shares.
The minimum investment for Concord Biotech Limited IPO is approximately ₹14,820 based on the upper price band .
Concord Biotech Limited IPO opens on Aug 4, 2023 and closes on Aug 8, 2023.
The allotment date of Concord Biotech Limited IPO is Aug 11, 2023.
Concord Biotech Limited IPO is expected to be listed on Aug 18, 2023, on BSE and NSE .
Concord Biotech Limited IPO listed on Aug 18, 2023. It was issued at ₹900.05(NSE) and is currently around ₹1131.00 as on 14-May-2026 3:30 PM, which is approximately 52.6% versus issue price. The 52-week high is ₹2,150.40.
Based on listing and post-listing performance, Concord Biotech Limited IPO delivered around 52.6% over issue price. Whether it was worth applying depends on your risk profile, allocation, and holding horizon.
To buy Concord Biotech Limited IPO shares after listing, log in to your broker app (such as Zerodha, Angel One, Groww, Upstox, ICICI Direct), search the stock symbol, place a delivery/CNC order, and confirm quantity and price.
Concord Biotech Limited IPO valuation snapshot: P/E 32.3, EPS ₹22.95/-, P/B N/A, RoNW 20.06%, and market cap N/A.
To apply for Concord Biotech Limited IPO, open the IPO Ji app or website, select the IPO, choose your demat account, enter the quantity, and submit the application.
You can check the live subscription status of Concord Biotech Limited IPO on IPO Ji or stock exchange websites. It shows real-time demand across retail, NII, and QIB categories.
Pre-apply allows investors to submit their IPO application before the bidding period starts. The order is placed automatically when the IPO opens.
If you pre-apply for Concord Biotech Limited IPO, your order will be placed when the IPO bidding starts, and a UPI mandate request will be generated.
You can check Concord Biotech Limited IPO allotment status on the registrar or stock exchange websites using your PAN or application number after allotment. You can also check the Concord Biotech Limited IPO allotment status on IPO Ji for quick and easy access.